These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21947196)

  • 1. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
    Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Dasou P; Parissis J; Nikolaou M; Markantonis SL; Katsimbri P; Skarantavos G; Andreadou I; Anastasiou-Nana M
    Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis.
    Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Andreadou I; Nikolaou M; Kaplanoglou T; Katsimbri P; Skarantavos G; Soucacos P; Kremastinos DT
    Heart; 2009 Sep; 95(18):1502-7. PubMed ID: 19482847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis.
    Ikonomidis I; Lekakis JP; Nikolaou M; Paraskevaidis I; Andreadou I; Kaplanoglou T; Katsimbri P; Skarantavos G; Soucacos PN; Kremastinos DT
    Circulation; 2008 May; 117(20):2662-9. PubMed ID: 18474811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.
    Ikonomidis I; Tzortzis S; Andreadou I; Paraskevaidis I; Katseli C; Katsimbri P; Pavlidis G; Parissis J; Kremastinos D; Anastasiou-Nana M; Lekakis J
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):619-28. PubMed ID: 24782115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).
    Abbate A; Kontos MC; Grizzard JD; Biondi-Zoccai GG; Van Tassell BW; Robati R; Roach LM; Arena RA; Roberts CS; Varma A; Gelwix CC; Salloum FN; Hastillo A; Dinarello CA; Vetrovec GW;
    Am J Cardiol; 2010 May; 105(10):1371-1377.e1. PubMed ID: 20451681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure.
    Kourea K; Parissis JT; Farmakis D; Panou F; Paraskevaidis I; Venetsanou K; Filippatos G; Kremastinos DT
    Atherosclerosis; 2008 Jul; 199(1):215-21. PubMed ID: 17991471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
    Li YJ; Ding WH; Gao W; Huo Y; Hong T; Zhu RY; Ma DL
    Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):548-53. PubMed ID: 15144587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor alpha and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules.
    Kobayashi T; Okamoto K; Kobata T; Hasunuma T; Kato T; Hamada H; Nishioka K
    Arthritis Rheum; 2000 May; 43(5):1106-14. PubMed ID: 10817565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A; Perniok A
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.